Connect with us

Hi, what are you looking for?

Home » India » DCGI Panel To Review Bharat Biotech, SII’s Application for Full Market Approval To Covaxin, Covishield


DCGI Panel To Review Bharat Biotech, SII’s Application for Full Market Approval To Covaxin, Covishield

Both Covaxin and Covishield are currently authorized for emergency use only.

Bharat Biotech's Covaxin and SII's Covishield got full market approval with conditions.

New Delhi: Subject Expert Committee of the Drugs Controller General of India (DCGI)’s will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, ANI sources said.

The SII of India had applied for market approval for the Covishield vaccine in December 2021 and Bharat biotech has also applied for the same 10 days ago.

According to a PTI report quoting official sources, V Krishna Mohan, director of the Bharat Biotech, had submitted a written application to DCGI for complete information along with pre-clinical and clinical data while seeking market authorisation for Covaxin.

Further, Bharat Biotech has informed that Covaxin is now a universal vaccine for adults and children. “Our goals of developing a global vaccine against COVID-19 have been achieved and all product development for licensure has been completed,” it said.

However, both Covaxin and Covishield are currently authorized for emergency use only.

ALSO READ: 2,64,202 New Covid-19 Cases, 315 Deaths Reported In Last 24 Hours, Omicron Cases Tally Reaches To 5,753

Since January 16, 2021, Covaxin has accounted for 12 per cent of the total Covid-19 vaccines administered in India. Additionally, it is the only vaccine dose administered to the age-group of 15-18 years, which began on January 3.

The expert panel of the Central Drugs Standard Control Organization (CDSCO) met on January 1 and January 2, 2021, and made recommendations in respect of the proposal for Restricted Emergency Approval of COVID-19 virus vaccines of Serum Institute of India and Bharat Biotech.

The SEC consists of domain knowledge experts from the fields of pulmonology, immunology, microbiology, pharmacology, pediatrics, internal medicine, etc.

It had reviewed the data on the safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in an emergency situation in the public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains. The clinical trial ongoing within the country by the firm will continue.

Advertisement. Scroll to continue reading.

SII and Bharat Biotech vaccines have to be administered in two doses. All three vaccines have to be stored at 2-8 degrees Celsius.

After adequate examination, CDSCO had decided to accept the recommendations of the Expert Committee and accordingly, SII’s Covishied and Bharat Biotech’s Covaxin were approved for restricted use in an emergency situation.

Notably, the administration of Covaxin and Covishield began on January 16, 2021, in the country.

ALSO READ: Omicron-Led Fourth COVID-19 Wave In Africa Flattening After Six-Week Surge: WHO

(With inputs from ANI)

Read Full Article



In at least four seats in Goa, including the prestigious Panaji constituency, BJP has witnessed dissent from former party members.


According to the designer, the blue pantsuit with black polka dots will make Minnie Mouse "A symbol of progress".


EVERY year as February nears, there’s much chatter about the Union Budget on every platform. If you’re a millennial, there’s a high chance that...


Two years on, eight countries have managed to stay away from the pandemic, reporting zero cases, and have remained largely untouched by the virus.


The pothole-ridden roads have become a nightmare for its residents in Bengaluru.

You May Also Like


Several students' organisations, including the All India Students Association (AISA), called for the state-wide bandh on Friday to protest against the alleged irregularities in...


The cause of death will be determined after the postmortem results.


Jats are a deciding factor in almost all the seats in western Uttar Pradesh, a region where the RLD enjoys influence among the community.


BrahMos missile deal is also India’s first major weapon sale.